Navigating large chemical spaces in early-phase drug discovery

被引:20
|
作者
Korn, Malte [1 ]
Ehrt, Christiane [1 ]
Ruggiu, Fiorella [2 ]
Gastreich, Marcus [3 ]
Rarey, Matthias [1 ]
机构
[1] Univ Hamburg, ZBH Ctr Bioinformat, Bundesstr 43, D-20146 Hamburg, Germany
[2] Insitro, 279 E Grand Ave, South San Francisco, CA 94608 USA
[3] BioSolveIT GmbH, Ziegelei 79, D-53757 St Augustin, Germany
关键词
DESIGN; SEARCH;
D O I
10.1016/j.sbi.2023.102578
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The size of actionable chemical spaces is surging, owing to a variety of novel techniques, both computational and experi-mental. As a consequence, novel molecular matter is now at our fingertips that cannot and should not be neglected in early-phase drug discovery. Huge, combinatorial, make-on-demand chemical spaces with high probability of synthetic success rise exponentially in content, generative machine learning models go hand in hand with synthesis prediction, and DNA-encoded libraries offer new ways of hit structure discovery. These technologies enable to search for new chemical matter in a much broader and deeper manner with less effort and fewer financial resources. These transformational developments require new chem-informatics approaches to make huge chemical spaces searchable and analyzable with low resources, and with as little energy consumption as possible. Substantial progress has been made in the past years with respect to computation as well as organic synthesis. First examples of bioactive compounds resulting from the successful use of these novel technologies demonstrate their power to contribute to tomor-row's drug discovery programs. This article gives a compact overview of the state-of-the-art.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Pharmacometabolomics in Early-Phase Clinical Development
    Burt, T.
    Nandal, S.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2016, 9 (03): : 128 - 138
  • [32] USE OF LARGE COMBINATORIAL CHEMICAL LIBRARIES FOR ANTICANCER DRUG DISCOVERY
    SALMON, SE
    LAM, KS
    FELDER, S
    YEOMAN, H
    SCHLESSINGER, J
    ULLRICH, A
    KRCHNAK, V
    LEBL, M
    INTERNATIONAL JOURNAL OF PHARMACOGNOSY, 1995, 33 : 67 - 74
  • [33] Early-phase trials of lipoprotein(a) lowering
    Gregory B. Lim
    Nature Reviews Cardiology, 2016, 13 (12) : 696 - 696
  • [34] Pharmacogenomics in early-phase clinical development
    Burt, Tal
    Dhillon, Savita
    PHARMACOGENOMICS, 2013, 14 (09) : 1085 - 1097
  • [35] Rapid Early-Phase Virtual Integration
    Mohan, Sibin
    Nam, Min-Young
    Pellizoni, Rodolfo
    Sha, Lui
    Bradford, Richard
    Fliginger, Shana
    2009 30TH IEEE REAL-TIME SYSTEMS SYMPOSIUM, PROCEEDINGS, 2009, : 33 - +
  • [36] Efficient Design of Integrated and Adaptively Interlinked Protocols for Early-Phase Drug Development Programs
    Coates, Simon
    Pohl, Oliver
    Gotteland, Jean-Pierre
    Taubel, Jorg
    Lorch, Ulrike
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2020, 54 (01) : 184 - 194
  • [37] Efficient Design of Integrated and Adaptively Interlinked Protocols for Early-Phase Drug Development Programs
    Simon Coates
    Oliver Pohl
    Jean-Pierre Gotteland
    Jörg Täubel
    Ulrike Lorch
    Therapeutic Innovation & Regulatory Science, 2020, 54 : 184 - 194
  • [38] Integration of science and business in early-phase chemical process development for active pharmaceutical ingredients
    Zhang, Tony
    DeVries, Keith
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 231
  • [39] THE RELATIONSHIP BETWEEN EARLY-PHASE SUBSTANCE-USE TRAJECTORIES AND DRUG COURT OUTCOMES
    Jones, Craig G. A.
    Kemp, Richard I.
    CRIMINAL JUSTICE AND BEHAVIOR, 2011, 38 (09) : 913 - 933
  • [40] New Chemical Modalities and Strategic Thinking in Early Drug Discovery
    Blanco, Maria-Jesus
    Gardinier, Kevin M.
    ACS MEDICINAL CHEMISTRY LETTERS, 2020, 11 (03): : 228 - 231